首页 › 基金 › Bellevue Group AG › DMRA
Bellevue Group AG 对 DMRA 的持仓历史
DAMORA THERAPEUTICS INC · 医疗保健
Bellevue Group AG 在 Q3 2026 的 13F 申报中披露持有 DMRA(DAMORA THERAPEUTICS INC)1,919,383 股,市值约 US$40.8M,约占其申报组合的 0.85%,在其申报持仓中市值排名第 30 位。 Bellevue Group AG 最近 3 个申报季度中有 3 个季度披露了 DMRA 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Bellevue Group AG 对 DMRA 的持仓演变
Bellevue Group AG 于 Q1 2026 首次披露 DMRA 持仓:2,298,000 股(约 US$59.5M)。 在 3 次申报中,Bellevue Group AG 1 次增持、1 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 1,919,383 股、市值约 US$40.8M,环比增持 300,537 股。。 持仓曾出现大幅变动:Q2 2026 减持约 30% (随后一个季度股价下跌 18%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 2.30M | $59.52M | 新进 |
| Q2 2026 | 1.62M | $42.11M | 减持 |
| Q3 2026 | 1.92M | $40.84M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 DMRA 与 13F 数据
DMRA(DAMORA THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 83 只申报持有 DMRA,申报仓位最大的包括:Fairmount Funds Management LLC (US$185.4M), Avoro Capital Advisors LLC (US$80.5M), Venrock Adviser, LLC (US$76.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 DMRA 的基金
- Fairmount Funds Management LLC 8.71M 股 · $185.41M · Q3 2026
- Avoro Capital Advisors LLC 3.78M 股 · $80.50M · Q3 2026
- Venrock Adviser, LLC 3.60M 股 · $76.68M · Q3 2026
- FCPM III SERVICES B.V. 2.44M 股 · $51.94M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 2.40M 股 · $51.07M · Q3 2026
- Remedium Capital Partners, LLC 2.05M 股 · $43.53M · Q3 2026
- Commodore Capital LP 1.94M 股 · $41.26M · Q3 2026
- BRAIDWELL LP 1.75M 股 · $37.19M · Q3 2026
- a16z Capital Management, L.L.C. 1.24M 股 · $26.31M · Q3 2026
- Siren, L.L.C. 900.00K 股 · $19.15M · Q3 2026
- Cormorant Asset Management, LP 800.00K 股 · $17.02M · Q3 2026
- STEMPOINT CAPITAL LP 506.07K 股 · $10.77M · Q3 2026
更多关于 Bellevue Group AG
常见问题
How long has Bellevue Group AG held DMRA?
Bellevue Group AG has disclosed DMRA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Bellevue Group AG's current position in DMRA?
As of Q3 2026, Bellevue Group AG holds 1.92M shares of DMRA (DAMORA THERAPEUTICS INC), valued at $40.84M, representing 0.85% of its reported portfolio and ranking #30.
Has Bellevue Group AG been buying or selling DMRA?
In the latest 13F filing (Q3 2026), Bellevue Group AG increased its position in DMRA.
Which other funds hold DMRA?
Other major institutional holders of DMRA include Fairmount Funds Management LLC, Avoro Capital Advisors LLC, Venrock Adviser, LLC, among 83 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.